2 reports of this reaction
1.2% of all GLYCERIN, PHENYLEPHRINE HCL, PRAMOXINE HCL, WHITE PETROLATUM reports
#19 most reported adverse reaction
CYSTITIS is the #19 most commonly reported adverse reaction for GLYCERIN, PHENYLEPHRINE HCL, PRAMOXINE HCL, WHITE PETROLATUM, manufactured by Amerisourcebergen Drug Corporation. There are 2 FDA adverse event reports linking GLYCERIN, PHENYLEPHRINE HCL, PRAMOXINE HCL, WHITE PETROLATUM to CYSTITIS. This represents approximately 1.2% of all 163 adverse event reports for this drug.
Patients taking GLYCERIN, PHENYLEPHRINE HCL, PRAMOXINE HCL, WHITE PETROLATUM who experience cystitis should discuss this symptom with their healthcare provider to determine whether it may be related to their medication and what alternatives may be available.
CYSTITIS is a less commonly reported adverse event for GLYCERIN, PHENYLEPHRINE HCL, PRAMOXINE HCL, WHITE PETROLATUM, but still significant enough to appear in the safety profile.
In addition to cystitis, the following adverse reactions have been reported for GLYCERIN, PHENYLEPHRINE HCL, PRAMOXINE HCL, WHITE PETROLATUM:
The following drugs have also been linked to cystitis in FDA adverse event reports:
CYSTITIS has been reported as an adverse event in 2 FDA reports for GLYCERIN, PHENYLEPHRINE HCL, PRAMOXINE HCL, WHITE PETROLATUM. This does not prove causation, but indicates an association observed in post-market surveillance data.
CYSTITIS accounts for approximately 1.2% of all adverse event reports for GLYCERIN, PHENYLEPHRINE HCL, PRAMOXINE HCL, WHITE PETROLATUM, making it a notable side effect.
If you experience cystitis while taking GLYCERIN, PHENYLEPHRINE HCL, PRAMOXINE HCL, WHITE PETROLATUM, contact your healthcare provider. They can evaluate whether the symptom is related to your medication and discuss potential adjustments to your treatment plan. Do not stop taking prescribed medication without consulting your doctor.